Monoclonal antibody to DR4 (Clone: ABM1B11 )
Fig.1: Expression analysis of DR-4. Anti-DR4 antibody (Clone: ABM1B11) was tested at 2 µg/ml on K562 lysate.
Roll over image to zoom in
Shipping Info:
Order now and get it on Wednesday April 08, 2020
Same day delivery FREE on San Diego area orders placed by 1.00 PM
Death receptor 4 (DR4) or TRAIL-R1, a member of the tumor necrosis factor receptor superfamily, is a cell surface receptor that triggers the apoptotic machinery upon binding to its ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. DR4 expression is enhanced by DNA damage whether induced by ionizing radiation or by chemotherapeutic agents. On binding DR4, TRAIL induces cell death via caspase-dependent apoptosis. DR4 mediate oligomeric Abeta induction of extrinsic apoptotic pathways in human microvascular cerebral endothelial cells with activation of both caspase-8 and caspase-9. It is considered a promising molecular target for cancer therapy.
| Purification : | Protein G Chromatography |
| Content : | 25 µg in 50 µl/100 µg in 200 µl PBS containing 0.05% BSA and 0.05% sodium azide. Sodium azide is highly toxic. |
| Storage condition : | Store the antibody at 4°C; stable for 6 months. For long-term storage; store at -20°C. Avoid repeated freeze and thaw cycles. |
Western blot analysis: 2-4 µg/ml, FACS analysis- 0.5-1 µg/10^6 Cells
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
| Subcellular location: | Membrane |
| Tissue Specificity: | Widely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells. |
| BioGrid: | 114325. 50 interactions. |
|
There are currently no product reviews
|
